When we examined the data from 172 tumors that were classified as Grade 3, ER negative basal-like breast cancer, a prognostic power of AXL was observed with poorer patient outcomes (p = 0.01) (Figure 5C). This evidence concerns the gene ESR1 and breast cancer.